Skip to main content
Premium Trial:

Request an Annual Quote

Silicon Valley Biosystems' Dx Lab Receives CLIA Certification

NEW YORK (GenomeWeb News) – Silicon Valley Biosystems today said that its in silico diagnostics laboratory has received CLIA certification from the California Department of Public Health.

The firm performs next-generation sequencing-based diagnostics on patient samples at the lab. It runs SV Bio's GermlineDx NGS interpretation platform, providing a "turnkey solution for clinical grade analysis and interpretation of single-gene, multi-gene, whole-exome, or whole-genome assays for germline indications, such as Mendelian disease diagnosis, carrier testing, hereditary cancer risk assessment, and pharmacogenomic applications," the firm said in a statement.

SV Bio also has a CLIA-certified ultra-high-throughput NGS wet lab for customers who need a complete solution, including generation of the genetic sequence, the company said.

Foster City, Calif.-based SV Bio was launched earlier this year and provides genomic data at the point of care. It and Mayo Clinic have an agreement to use each other's technologies to improve accessibility and the clinical use of next-generation sequencing for patients.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.